CytoDyn reveals positive data on metastatic triple-negative breast cancer trial

CytoDyn Inc (OTCMKTS: CYDY) Chief Executive Officer Nader Pourhassan tells Aggressive it has actually launched extra early Phase 1b/2 scientific trial outcomes of its lead medication leronlimab in people with CCR5 metastatic triple-negative bust cancer.

Pourhassan states representatives from its lab called him sobbing, disclosing the patient’s lump had diminished. Pourhassan says data from the first patient registered show no obvious flowing lump cells (CTC) in the outer blood with additional decreases in CCR5 expression on cancer-associated cells at eight weeks.